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Abstract Estrogens are the subject of intensive researches
aiming to elucidate their mechanism of action on the various
tissues they target and especially on mammary gland and
breast cancer. The use of ready-to-use slow releasing devices
to administer steroids, especially estrogens, to small experi-
mental animals remains the method of choice in terms of an-
imal well-being and of safety for both the researcher and the
animal. In this study, we evaluated and compared, in vitro and
in vivo, the release kinetic of estradiol (E2) over sixty days
from two different slow-releasing systems: the matrix pellet
(MP) and the reservoir implant (RI). We compared the impact
of these systems in three E2-sensitive mouse models : mam-
mary gland development, human MCF7 adenocarcinoma xe-
nograft and mouse melanoma progression. The real amount of
E2 that is released from both types of devices could differ
from manufacturer specifications due to inadequate release
for MP and initial burst effect for RI. Compared to MP, the
interindividual variability was reduced with RI thanks to a
superior control of the E2 release. Depending on the dose-
dependent sensitivity of the physiological or pathological
readout studied, this could lead to an improvement of the
statistical power of in vivo experiments and thus to a reduction
of the required animal number. Altogether, our data draw
attention on the importance to adequately select the slow-
releasing device that is the most appropriated to a specific
experiment to better fulfill the 3Rs rule (Replacement, Re-
duction, Refinement) related to animal welfare and protection.
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Introduction
Estrogens play a key role in sexual development and repro-
duction. They are also implicated in a large number of other
physiological and pathological events including cancer pro-
gression [1–8]. The elucidation of the molecular mechanisms
sustaining steroid action on the various tissues they target and
especially on mammary gland and breast cancer is the subject
of intensive researches. The development of selective estrogen
receptor modulators (SERM), such as tamoxifen, has provid-
ed important improvement for the treatment of estrogen recep-
tor (ER)-positive breast cancer [9, 10]. The use of animal
models, especially rodents, is crucial for elucidating the bio-
logical effects and molecular mechanisms of 17β-estradiol
(E2) and SERMs. A substantial part of the experimental ani-
mal studies have been conducted in ovariectomized rodents
receiving exogenous E2, to avoid the cyclic influence of ovar-
ian hormones [11–16]. However, there is a lack of consensus
about the optimal means to reach appropriate E2 plasma con-
centrations and maintain long-term steady state E2 plasma
level.
Estrogens are usually administered orally to humans.
Several oral administration formulations have been developed
for rodents and include gavage, food-mixture preparations
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[17, 18] or supplemented drinking water [19, 20]. These
methods present several drawbacks such as stressful animal
handling, difficulty of mixing hydrophobic estrogens in water,
impossibility to precisely control the individual intake or in-
duction of pulsatile concentration of E2 in plasma. The other
modes of administration are daily subcutaneous injections or
subcutaneous implanted slow-releasing devices [21]. These
slow-release formulations have clear benefits as they are eas-
ily inserted by a single light surgery, they do not require daily
stressful animal manipulation and they avoid pulsatile concen-
tration observed with daily injections.
Based on drug release mechanisms [22], slow-releasing
devices are classified in three categories: osmotic systems,
matrix systems and reservoir systems.
The Alzet® system is based on the osmotic pumping mech-
anism and consists of an osmotic compartment surrounded by
a semi-permeable membrane with a single delivery orifice. In
an aqueous environment, water is imbibed through the semi-
permeable membrane, generates an osmotic flux and builds up
a hydrostatic pressure pushing the drug solution out of the
implant through the orifice. The drug release rate is generally
constant as long as the osmotic driving force from the water
influx is constant. The maximum release time is six weeks for
small animals (www.alzet.com). Although this system is more
appropriated for highly water soluble active agents, it can be
used for steroids but it is necessary to solubilize them first in
ethanol.
In a matrix device, the drug is dissolved or dispersed in a
polymeric carrier or lipid matrix. In this system, drug mole-
cules can elute out of the matrix by dissolution or erosion in
the surrounding excipient and diffuse through the matrix
structure, without any control of the release. As consequence,
the drug release is not constant and decreases over time, pro-
portionally to the square root of time. Slow-release matrix
pellet are commercially available for several steroids and
SERMs, in a large range of concentrations, covering 21 to
90 days of release (www.innovrsrch.com).
In the reservoir system, the drug core is surrounded by a
rate-controlling membrane. Drug diffusion is driven by the
drug concentration gradient across the membrane, according
to the first order law of Fick. As a large excess of drug is
present inside the reservoir to maintain saturation on the up-
stream side of the membrane, a constant rate of drug release is
preserved. Administration of steroids by reservoir systems can
be achieved either by newly commercially available implants
(http://www.belmatech.com/en/) or by home-made silastic®
capsules. However, the home-made silastic® capsules imply
the preparation of the active agent dispersed in oil or mixed
with cholesterol powder in various proportion and the filling
of the silastic® tube (inner diameter ± 1.5 mm) [17, 18, 23].
It is important to mention that steroid manipulation carry
some health hazards. Handling of hormones in crystalline
powder form or in solution must occur in a functional fume
hood with appropriate protection for the staff. Risks include
fertility damage and carcinogenicity, besides of clothes and
environment contamination (see safety data sheet such as
http://www.caymaneurope.com/msdss/10006315m.pdf). For
all these reasons and because subcutaneous implantable
devices must fulfill criteria like sterility and apyrogenicity,
ready-to-use commercial slow-releasing devices present sig-
nificant advantages in terms of safety and represent the device
of choice for experimental research on rodent.
Different drug release devices could induce variations in
term of drug pharmacokinetic and thus could influence the
physiological endpoints being measured in an experiment.
The aim of the present study was: 1) to evaluate and compare,
in vitro and in vivo, the release kinetic of E2 over sixty days of
two industrially manufactured implantable formulations (ma-
trix pellet (MP) from Innovative Research of America (IRA),
and reservoir implant (RI) from Belma Technologies (BT)),
and 2) to investigate the impact of these systems on three E2-
sensitive mouse models: mammary gland growth, human
mammary tumor xenografts and mouse B16K1 melanoma.
Materials and Methods
Chemicals
Slow-release matrix pellets (MP) were purchased from IRA
(SE-121, Sarasota, FL, USA). Reservoir implants (RI) for rat
and mouse were purchased from Belma Technologies (RE2–
60/ME2–60, Liège, Belgium). E2 (purity ≥98%) was pur-
chased from Nanjing Hanchen Medical & Chemical Co.,
Ltd. (Nanjing, China). Deuterium labeled internal standard
(IS) 17β-estradiol-2, 4, 16, 16, 17-d5 (d5-E2) was obtained
from C/D/N Isotopes Inc. (Quebec, Canada). HPLC grade
methanol was from J.T. Baker® (Deventer, Netherlands) and
ultrapure water was dispensed from a Milli-Q purification
system (Millipore Corporation, Bedford, MA, USA).
Phosphate buffer (pH 7.4; 50 mM) was prepared with sodium
hydroxide from VWR (Leuven, Belgium), and with potassi-
um dihydrogen phosphate and sodium azide from Merck
(Darmstadt, Germany).
In Vitro Drug Release
MP (0.01 and 1.7 mg/60 days) and RI (ME2/60 days,
ME2L/60 days and RE2/60 days) were placed in amber bot-
tles containing 200 ml of phosphate buffer at pH 7.4 and
maintained in a 37 °C water bath agitating at 140 rpm [24].
E2 concentration was determined after 1, 2, 3, 7, 10, 14, 21,
28, 35, 43, 49, 56 and 63 days. To respect sink condition,
release medium was completely withdrawn and replaced with
fresh buffer 24 h before each time point. Sample aliquots were
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then taken and E2 was quantified using LC-MS/MS technique
as detailed below.
LC–MS/MS Analysis
Chromatographic separation was achieved on a Agilent HP
1100 series (Agilent Technologies, Waldbronn, Germany)
controlled by a LC Chemstation. MS detection was carried
out using an Ultima triple quadrupole instrument
(Micromass, Manchester, United Kingdom) operating under
MassLynx 4.1 (Waters) and configured with a Z-spray
electrospray ionization source operating in the negative ion
mode. The isocratic separation was performed on a
150 mm × 2.1 mm Altima C18 column with 3 μm particles
(Grace, Lokeren, Belgium) using a mobile phase consisting in
a mixture of methanol and purified water (60/40, v/v). The
flow rate was settled at 0.3 ml/min, the sample injection vol-
ume was of 20 μL and the column temperature was 35 °C.
Multiple reaction monitoring (MRM) mode was used to mon-
itor E2 at m/z 271/183 and 271/145, and the internal standard
d5-E2 at m/z 276/187.
The e-noval software v3.0 (Arlenda S.A., Liège, Belgium)
was used to validate the analytical method. Six point calibra-
tion curves were constructed and the linearity was determined
by plotting the peak area ratio of E2 to d5-E2 versus the hor-
mone concentration. Standard curves were generated from
four independent runs. Good linearity was obtained with a
weighted (1/X2) quadratic regression. Curves were linear from
1 to 500 ng/ml and correlation coefficients (r2) ranged from
0.9977 to 0.9986. The detection limit was 0.16 ng/ml.
Validation experiments were made by means of four
series (one series per day). Trueness expressed in term
of relative bias (%) was assessed from the validation
standards at seven concentration levels and ranged from
−2.304 to 3.860. The precision was then determined by
computing the relative standard deviation for repeatability and
between-series intermediate precision at each concentration
level of validation standards. Values ranged from 2.523 to
5.241 and from 3.265 to 6.267 respectively depending on
the concentration level.
Hormone Assays
Electrochemiluminescence immunoassay (ECLIA) on a
Modular Analytics E analyzer (Roche, Basel, Switzerland)
was used to determine plasma samples concentration of E2.
According to the manufacturer, measuring range of the master
curve was from 5 to 4300 pg/mL which defined the lower and
the maximum detection limits. Repeatability and intermediate
precision ranged from 2.4–4.6% and 4.3–9.9% respectively
depending on the concentration level. The entire analysis
was performed in a single run.
Ethic Statement of in Vivo Studies
All experimental procedures and protocols used in this inves-
tigation were reviewed and approved by the Institutional
Animal Care and Use Ethics Committee of the University of
Liège (Belgium). The BGuide for the Care and Use of
Laboratory Animals^, prepared by the Institute of
Laboratory Animal Resources, National Research Council,
and published by the National Academy Press, was followed
carefully as well as European and local legislation. Animal
welfare was assessed at least once per day with humane end-
points applied when necessary as described in the ethical
form.
In Vivo Drug Release
Ovariectomized Sprague Dawley female rats weighing ap-
proximately 300 g were purchased from the Central Animal
Facility of the University of Liège -LA2610359-, Belgium.
Rats were subcutaneously (s.c.) implanted with a 1.7 mg/
60 days MP (n = 6) or with a RE2/60 days RI (n = 6).
Blood samples were collected after 5, 12, 19, 32, 47 and
60 days by tail lateral vein puncture into heparinized Tube
(Multivette®600 Tubes, Sarstedt, Essen, Belgium).
Ovariectomized mice were s.c. implanted with ME2/60 days
or ME2L/60 days RI. Blood were collected by cardiac punc-
ture into serum tubes (Minicollect® Tubes, Greiner bio-one,
Vilvoorde, Belgium) at 2, 7, 14, 28 and 63 days. Blood sam-
ples were centrifuged at 2,500×g for 10 min. Plasma samples
were kept at −20 °C until analysis. Uterus were weighted,
collected, fixed using 4% formalin and embedded in paraffin
for histological analysis at each time point. Sections were cut
at 6 μm, deparaffinised in xylene and rehydrated through
graded alcohols, then stained with hematoxylin/eosin.
Mammary Gland Model
C57BL/6 female prepubertal mice (4 weeks, n = 20) were
purchased from Janvier Laboratory (Saint-Berthevin, France)
and ovariectomized under isoflurane anesthesia to remove en-
dogenous ovarian hormone production. Mice were housed
under a standard 12-h photoperiod with food and water pro-
vided ad libitum. Treatments were initiated at 35 days of age
for a period of 14 days. Mice (5 animals in each group) were
fed by gavage with peanut oil containing 5% ethanol (vehicle,
negative control) or with E2 (1 mg/kg/day), or were implanted
s.c. with either a ME2/60 days RI or with a MP of E2
(0.01 mg/60 days). At the end of the treatment, mice were
euthanasized and mammary tissues were dissected for whole
mount preparation. One of the fourth inguinal mammary
glands was removed in one piece and spread onto a glass slide.
The removed gland was subjected to whole-mount fixation,
defatting and staining. The mammary glands were fixed in
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Carnoy’s fixative (ethanol, chloroform, glacial acetic acid;
6:3:1) for at least 4 h and defatted in acetone over-night.
They were then re-hydrated through a series of graded alco-
hols and stained with carmine overnight. Whole mount glands
were then dehydrated sequentially through 70%, 90% and
100% ethanol for 20 min each and cleared in xylene for at
least 2 h. Digital pictures of mammary glands immersed in
xylene were taken using a LeicaM80microscope with a Leica
IC80 HD digital camera attached. Image processing and mor-
phological measurements were performed as previously de-
scribed [25].
Adenocarcinoma Tumor Model
Swiss nu/nu (7 weeks, n = 18) female mice were purchased
from Charles River Laboratories-France. Prepubertal mice
were ovariectomized under isoflurane anesthesia to remove
endogenous ovarian hormone production. Four days before
cancer cell injection, mice were implanted s.c. either with a
1.7 mg/60 days MP or with a ME2/60 days RI, or were sham
operated (untreated control group). Human adenocarcinoma
MCF7 cells were used as previously described [14]. Tumor
cells (1 × 106 cells suspended in 200 μl of Matrigel) were
injected s.c. to both flanks of mice. Tumors were measured
every 2 to 3 days with digital caliper and tumor volume was
calculated as V (mm3) = a x b2 × 0.52 (n = 12 tumors per
experimental group). At sacrifice, tumors were immediately
resected and weighed. The bladder, uterus and kidneys were
also dissected, fixed using 4% formalin and embedded in par-
affin for histological analysis. Sections were cut at 6 μm,
deparaffinised in xylene and rehydrated through graded alco-
hols, then stained with hematoxylin/eosin. We systematically
checked that E2-untreated ovariectomized mice had an
atrophied uterus (<10 mg) and that those implanted with an
E2-releasing pellet had a significant increase of uterine
weight.
Melanoma Tumor Model
C57BL/6 J (4 weeks, n = 18) female mice were purchased
from Charles River Laboratories-France. Mice were ovariec-
tomized under isoflurane anesthesia to remove endogenous
ovarian hormone production. Two weeks before cancer cell
injection, mice were implanted s.c. either with a 0.01 mg/
60 daysMP or with aME2/60 days RI, or were sham operated
(untreated control group). Mouse melanoma cell line B16K1
(MHC class I–positive B16F10) was used as previously de-
scribed [16]. Tumor cells (4 × 105 cells suspended in PBS)
were injected s.c. to both flanks of C57BL/6 J mice. Tumors
weremeasured every 2 to 3 days with digital caliper and tumor
volume was calculated as V (mm3) = a x b2 × 0.52 and
expressed as mean tumor volume (12 tumors per experimental
group). At sacrifice, tumors were immediately resected and
weighed. We systematically checked that E2-untreated ovari-
ectomized mice had an atrophied uterus (<10 mg) and that
those implanted with an E2-releasing pellet had a significant
increase of uterine weight.
Statistical Analysis
All quantitation experiment data are expressed as mean ± SD
ormean ± SEM. Data frommammary gland experiments were
analyzed by Kruskal-Wallis test and Dunn’s post test. A two-
way ANOVAwas used for in vivo tumor growth comparisons.
Statistical analysis were conducted with GraphPad Prism soft-
ware. The value of p ≤ 0.05 was considered as statistically
significant.
Results
In Vitro Drug Release Kinetics
In vitro E2 release kinetic profiles from two MP and three RI
slow-releasing devices are illustrated in Fig. 1. Among the
available MP, we tested doses of 1.7 mgE2/60 days and of
0.01 mgE2/60 days. BothMP presented a small but long burst
effect. For MP 1.7 mg, the mean amount of released E2 was
16.3 ± 2.9 μg/24 h on day 1 (Fig. 1a). Then, it decreased
progressively from day 1 to day 35 to reach a stable mean
amount of 4.9 ± 0.8 μg/24 h from day 35 to day 63. These
released amounts were significantly lower than those an-
nounced by the manufacturer (28.33 μg/24 h along 60 days).
In accordance, the ratios between measured and expected
AUC calculated at different time points along the kinetic were
included between 0.53 and 0.27 (Fig. 1f).MP 0.01mg/60 days
was expected to deliver 0.17 μg E2/24 h accordingly to the
manufacturer specifications. The mean amounts of E2 re-
leased decreased from 9.1 ± 0.2 μg/24 h at day 2 to undetect-
able level after 35 days while this device was supposed to
release for 60 days (Fig. 1b). The mean E2 release between
day 3 and day 35 was 1.8 ± 1.6 μg/24 h, an unexpected 10
times higher amount than the expected one. The AUC ratios
were far from 1, varying from 43.9 to 0 along the kinetic
(Fig. 1f). At each time point, the coefficient of variation
(CV) of the E2mean release byMPwas high ranging between
13 and 66%.
All RI devices (RE2, ME2, ME2L) showed similar release
profiles (Fig. 1c-e). After a sharp burst effect of 3 days, the RI
release kinetics followed a linear steady state period till the
end of the tested period (day 63). For RE2 (Fig. 1c), the mean
amount of E2 released was 22.6 ± 0.9 μg/24 h at day 1, a 4.5
times higher amount than the 5 μg/24 h given by the manu-
facturer specifications. It fell to 6.8 ± 1.3 μg/24 h at day 3 and
then remained stable with a mean released amount of
5.9 ± 1.2 μg/24 h from day 3 to day 63. For ME2 (Fig. 1d),
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the mean E2 amount was 18.5 ± 0.9 μg/24 h at day 1, a 12
times higher amount than the 1.5 μg/24 h given by the man-
ufacturer specifications. Then, from day 3 to day 63, the mean
release was 1.6 ± 0.5 μg/24 h. For ME2L (Fig. 1e), the mean
E2 reached 3.20 ± 0.05 μg/24 h at day 1, a 4.3 times higher
amount than the 0.75 μg/24 h given by the manufacturer spec-
ifications. At day 3, the mean daily release of E2 fell at
1.26 ± 0.02 μg/24 h to reach a stable amount of
0.71 ± 0.02 μg/24 h from day 14 till day 63. After the burst
period of 3 days, these values were consistent with the man-
ufacturer’s specifications. For the three RI devices, the range
of AUC ratios at day 3 was 5.4 to 2.6, reflecting the initial
burst. Then it varied from 2.9 to 1.1. For all RI devices, the CV
of released concentrations remained under 6%.
In Vivo E2 Plasma Levels
The reported physiological range of E2 plasma concentration in
rodents is 2.4 to 145 pg/ml [18]. E2 plasma levels obtained in rat
over a period of 60 days with MP 1.7 mg/60 days and with RI
RE2/60 days are shown in Fig. 2a. Subcutaneously implanted
MP 1.7 mg led to supra physiological plasma concentrations
with a great variability during the first 3 weeks (mean
CV = 50%). It induced a burst reaching a mean E2 plasma
concentration of 553 ± 175 pg/ml in plasma after 12 days.
Subsequently, the concentrations decreased considerably until
day 32 and then remained stable with an average concentration
of 177 ± 52 pg/ml that is close to the upper values of the phys-
iological range. E2 plasma concentrations obtained after s.c. RI
(RE2) insertion showed a starting burst reaching 193 ± 22 pg/ml
after 5 days. Then, after 12 days, E2 plasma concentration was
108 ± 9 pg/ml and was thereafter maintained within the physi-
ological range during the entire experiment (mean CV = 15%).
RI ME2 caused an initial burst in mice E2 plasma level of
217 ± 39 pg/ml at day 2 (Fig. 2b). Then it reached physiological
concentrations after 7 days (106 ± 13 pg/ml). A steady-state
release, giving a mean of 38 ± 11 pg/ml plasma concentration,
was observed from day 14 during the entire experiment. Plasma
concentrations produced by RI ME2L stood within the physio-
logical range during the entire experiment, starting at
135 ± 13 pg/ml at day 2 to reach a steady-state release of
28 ± 6 pg/ml. Individual variations remained low (within 10%).
Histological sections (Fig. 2c), endometrial luminal epithe-
lial height (LEH) (Fig. 2d) and wet weight (Fig. 2e) of uterus
collected revealed a higher impact of RI ME2 than RI ME2L
after 2 days of treatment. However, from day 7 to 63 of expo-
sure, the uterine wet weights increased progressively with no
significant difference at each time point between both
Fig. 1 In vitro E2 release
kinetics. Timeline of in vitro
release of E2 MP 1.7 mg/60 days
(a), MP 0.01 mg/60 days (b), RI
RE2/60 days (c), RIME2/60 days
(d) and ME2L/60 days (e), over a
63 day period. Dot lines
correspond to the expected
amount of E2 in accordance with
the manufacturer data sheet.
Results are expressed in μg/24 h
as mean ± SD, n = 3. f AUC from
measured and expected E2 release
evaluated at different time points
on graphs A to E. AUC ratio
corresponds to AUC measured
divide by AUC expected
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treatments. Uterus treated with MP 1.7 mg or RI ME2 pre-
sented the same histological characteristics and luminal epi-
thelial height after 8 weeks of treatment (Fig. 2f-g). However,
interindividual variability was higher with MP device.
Mammary Gland Growth
The in vivo impact of E2-releasing MP and RI devices was
analyzed on mammary gland growth of ovariectomized mice
Fig. 2 In vivoE2 release kinetics. a Plasma E2 concentrations measured,
over a 63 day period, in plasma of ovariectomized rats following the
subcutaneous implantation of MP (1.7 mg/60 days) or RI (RE2/
60 days). Results are expressed as mean ± SEM, n = 6. b Plasma E2
concentrations measured, over a 63 day period, in plasma of
ovariectomized mice following the subcutaneous implantation of RI
(ME2/60 days or ME2L/60 days). Results are expressed as
mean ± SEM, n = 4. The grey field represents the physiological E2
range in rodent. Results from day 14 to 63 are zoomed in the small
upper graph. c Representative histological sections of uterus stained
with hematoxylin/eosin, harvested from day 2 (D2) to day 63 (D63) from
ovariectomized mice (OVX) or from ovariectomized mice either treated
with RI ME2/60 days or with RI ME2L/60 days. Scale bar = 200 μm. d
Luminal epithelial height (LEH) of uterus after 2 days of treatment, re-
sults are expressed in box plots presenting the median and wiskers (min to
max), n = 4, *p < 0.05. e Uterus wet weight of ovariectomized mice
following the subcutaneous implantation of RI (ME2/60 days or
ME2L/60 days). Dotted line represents the uterus wet weight of OVX
mice. Results are expressed as mean ± SEM, n = 4, *p < 0.05. f
Representative histological sections of uterus stained with hematoxylin/
eosin, harvested from ovariectomized mice treated either with MP
(1.7 mg/60 days) or RI (ME2/60 days) for 8 weeks, scale bar = 1 mm.
g Luminal epithelial height (LEH) of uterus after 8 weeks of treatment,
results are expressed in box plots presenting the median and wiskers (min
to max), n = 5
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and compared to E2 oral administration (Fig. 3a) used as pos-
itive control as previously reported [13]. In this previous
study, we established that oral administration of 1 mg/kg/day
of E2 led to a serum concentration of 171 ± 15 pg/ml
(0.63 nM) close to the upper range of physiological concen-
trations [18]. The mammary gland growth rate was quantified
by computer assisted image analysis, by measuring the total
length and total area of the epithelial ductal tree as previously
described [25]. In the present study, we compared the efficacy
of MP 0.01 mg E2 and RIME2 since both deliver comparable
amounts of E2 from 2 to 14 days (see in vitro kinetics Fig. 1b
and d). After 14 days of E2 treatment, the average length and
area of the epithelial network were significantly increased
with both MP (0.01 mg/60 days) and RI (ME2/60 days) de-
vices (Fig. 3b-c). Ductal tree length reached 119 ± 59 mm and
157 ± 67 with MP 0.01 and RI ME2 respectively. Ductal tree
area was 5.4 ± 2.4 mm2 and 7.3 ± 2.8 mm2 with MP 0.01 and
RI ME2 respectively. There was no statistical difference be-
tween both devices.
Human MCF7 Adenocarcinoma Xenograft
The xenograft of human MCF7 breast cancer cells is a com-
monly used in vivo model to study estrogen-dependent breast
cancer. The most commonly used and recommended E2-
delivering device for this model is the MP 1.7 mg/60 days,
which delivers a plasma E2 concentration of 550–900 pg/ml
[26, 27] and allows the proliferation of estrogen-dependent
tumor cells [6, 14, 28]. In this set of experiment, we compared
the efficiency of MP (1.7 mg/60 days) and of RI (ME2/
60 days) to promote MCF7 tumor growth in vivo. At the
end of the experiment the E2 plasma concentrations were
603 ± 50 pg/ml and 30 ± 7 pg/ml for MP 1.7 mg and RI
ME2 treated groups respectively. Both MP and RI devices
equally enhanced tumor growth (Fig. 4). Upon sacrifice of
MP treated mice, urethral occlusion, leading to urine retention,
caused by bladder stone formation was observed in 3 out of 6
mice (Fig. 5a-b). No such complication was observed in any
RI treated mice (Fig. 5c).
Mouse Melanoma Graft
The B16K1 melanoma tumor model was previously devel-
oped using MP with a low dose of E2 (0.01 mg/60 days)
[16]. This MP device was compared to the use of RI ME2/
60 days (Fig. 6) that presented a close in vitro pharmacody-
namics (see Fig. 1b-d-f). At the end of the experiment the E2
plasma concentrations were 32 ± 22 pg/ml and 35 ± 6 pg/ml
for MP 0.01mg and RIME2 treated groups respectively. Both
devices induced an overall similar increase of tumor growth
compared to OVX group (Fig. 6a), even if the data obtained
with RI ME2/60 days were statistically more robust. The tu-
mor weights were not significantly increased in animal treated
with MP device in comparison with the untreated mice
(Fig. 6b). This could be due to large interindividual variations
observed both in tumor weight and plasma E2 concentration at
the end of the experiment. In animal treated with RI the tumor
weights were significantly increased with a low interindivid-
ual variation.
Fig. 3 Mouse mammary gland growth. a Representat ive
photomicrographs of whole mount mouse mammary gland stained with
carmin from ovariectomized (OVX) mice or from ovariectomized mice
treated with E2 1 mg/kg/day administered by oral gavage (oral), with MP
0.01 mg/60 days (MP) or with RI RE2/60 days (RI), scale bar =1.6 mm.
Quantitative analysis of mammary gland development assessed by the
automated detection of the ductal tree length (b) or of the ductal tree area
(c). Ovariectomizedmice (OVX)were treated or not with E2 1mg/kg/day
administered by oral gavage (oral), with MP 0.01 mg/60 days (MP:0.01)
or with RI ME2/60 days (RI:ME2). Results are expressed as
mean ± SEM, n = 5 per treatment group. *p < 0.05, ***p < 0.001 vsOVX
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Statistical Power Analysis
A statistical power analysis using the standard deviations was
performed on the data obtained with the melanoma experi-
ment on day 14. If an expected mean tumor size of 900 mm3
is computed for the treated group, a statistical power of 0.80 is
achieved with n = 7/group for MP, whereas RI requires only
n = 3/group to reach a similar statistical power. Conversely, a
higher statistical power is achieved with the RI for a given
number of subjects per group. For example, with n = 5/group,
a statistical power of 0.63 is achieved with MP, whereas a
statistical very close to 1.00 is obtained with RI.
Discussion
The use of ready-to-use commercial slow releasing devices to
administer steroids, especially estrogens, to small experimen-
tal animals remains the method of choice in terms of animal
well-being and of safety for both the researcher and the ani-
mal. In this study, we evaluated and compared the release
kinetic of E2 over sixty days from two different slow-
releasing systems MP and RI. We here observed that the real
amount of E2 that is released from these devices could differ
from manufacturer specifications. The MP we tested did not
deliver the expected amount of E2. The RI presented a sharp
but short initial burst before reaching the expected delivery
amount. The interindividual variability was reduced with RI
devices compared to MP. These observations could impact the
design, the reliability and the reproducibility of preclinical
animal studies, depending on the sensitivity of the physiolog-
ical or pathological readouts.
Kinetics comparing the release of E2 from MP or RI sys-
tem revealed, both in vitro and in vivo, the induction of a
starting burst effect that could be a potential limitation espe-
cially for highly sensitive dose-dependent tissue targets.
In vitro kinetics revealed a sharp but short initial burst for RI
systems. MP devices presented smaller but longer burst than
RI. In vivo, the initial bursts were limited to 1 week with the
RI system, although it was observed along at least 3 weeks
Fig. 4 MCF7 adenocarcinoma xenograft. a In vivo growth curves of
human adenocarcinoma MCF7 tumors growing in ovariectomized
Swiss nu/nu mice treated with MP 1.7 mg/60 days or with RI ME2/
60 days. Results are expressed as mean ± SEM, n = 12. b Dot graph of
tumor weight at sacrifice, median is presented
Fig. 5 Bladder stone formation. a, b Representative photomicrographs
of hematoxylin/eosin staining of bladder from Swiss nu/nu mice
supplemented with MP 1.7 mg/60 days for 8 weeks. Stone formation in
the bladder lumen is pointed by the arrow. Scale bar = 1.5 mm (a), scale
bar = 800 μm (b). c Representative photomicrograph of hematoxylin/
eosin staining of bladder from Swiss nu/nu mice supplemented with RI
(ME2/60 days). The absence of stone formation in the lumen is
highlighted by the arrow, scale bar = 1.5 mm
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with the MP. The in vitro kinetics we performed suggest that a
3 day pre-incubation of RI devices in phosphate buffer before
s.c. implantation in rodent could prevent this starting burst.
However, a pre-incubation of MP systems is not recommend-
ed due to the risk of pellet disintegration. The variations be-
tween both devices can be explained by differences in the
mechanism of diffusion.
Surprisingly, both MP devices were far from delivering the
expected amount of E2. For MP 0.01 mg/60 days, the amount
of E2 that was released was 44 to 13 times too elevated. It
decreased continuously to an undetectable level after 35 days
when it was supposed to release during 60 days. In vitro, we
showed that the MP 1.7 mg/60 days released only the half of
the expected amount of E2. This device was supposed to re-
lease a supra physiological dose of 1.1 mg/kg/day in mice and
a physiological dose of 0.09 mg/kg/day in rats. The plasma
concentrations we measured from rats fluctuated from
supra physiologic (± 500 pg/ml) to physiological ones
(± 180 pg/ml). These data are in accordance with the
observations of other authors that have evaluated kinet-
ics of several E2 MP doses in ovariectomized mice [17]
and rats [18, 21, 23, 29]. After day 12–14, the kinetics
obtained with the RI systems in rats and mice presented
a steady-state level that was maintained along 7 weeks,
following a quasi-zero order kinetic. This stable kinetic
is particularly interesting since the assessment of E2
plasma concentration is most often measured at only
one time point from plasma obtained during the sacri-
fice of the animals. However, if a specific experimenta-
tion requires an accurate steady-state release within the
14 days following RI implantation, this initial burst
could be a limitation of RI devices. Altogether, these
observations have a major impact on the design of ex-
perimental protocols, if a specific dose and a stable and
reliable treatment is required.
Analysis of uterus histology, luminal epithelial height and
wet weight revealed that this tissue is dose-dependent sensi-
tive to E2 under acute short-term administration (2 days in this
study). Uterus wet weight increased for all conditions along
time exposure, reaching 0.14 to 0.19 g. However, after 1 week
of treatment, there was no difference between the various
doses and devices administrated (RI ME2, RI ME2L, MP
1.7 mg) in term of wet weight and histological characteristics.
These observations are corroborated by the study of Abot et al.
[30] who reported that a chronic administration of E2 by MP
0.01 mg induced uterine wet weight of 0.15 g, although it was
of 0.02 g after 24 h of treatment with E2 8 μg/kg/day.
To our knowledge, subcutaneous slow-release formula-
tions were not usually used to study the impact of E2 on
mammary gland. Subcutaneous injections or oral administra-
tions were more often reported [13, 25, 31]. Based on the
specifications provided by the manufacturers, MP 0.01 mg
should release 0.17 μg/24 h and RI ME2 1.5 μg/24 h.
However, our in vitro release study showed that both devices
released comparable amount of E2 from day 2 to day 28. If
both devices stimulate ductal tree elongation, RI ME2 has a
tendency to produce a higher effect. This could be explained
by the acute burst observed with RI ME2 at day 1. Our results
clearly show that E2 administered with MP or RI devices
could be an interesting alternative for such experiments per-
formed on long-term period. However, attention should be
paid to choose a device and a dose that fits the best to a defined
experimental design.
In the human adenocarcinoma MCF7 tumor xenograft
model, our results clearly show that the supra physiological
dose of E2 usually administered with MP [6, 14] are not nec-
essary to allow the proliferation of estrogen-dependent tumor
cells. These data corroborates the observations of Dall et al.
[26]. Indeed, the RI ME2 was sufficient to induce similar
tumor growth kinetic. To note, we observed that despite an
initial burst reaching a plasma concentration of 217 pg/ml at
day 2, this device released physiological concentrations of E2
from day 7. This is of great interest since several studies [20,
32–34] reported that high doses of E2, administered for long-
term period, are associated with renal damage, urethral occlu-
sion and bladder stone formation, corroborating our observa-
tions with E2 MP 1.7 mg/60 days used along a period of
8 weeks. The use of RI (ME2/60 days) releasing long-term
physiological dose of E2 appears more appropriate since no
Fig. 6 B16K1 melanoma graft. a In vivo growth curves of melanoma
B16K1 tumors injected in ovariectomized mice (OVX) treated with MP
(0.01 mg/60 days) or with RI (ME2/60 days). Results are expressed as
mean ± SEM, n = 9 to 12, **p < 0.01, ***p < 0.001 vs OVX. bDot graph
of tumor weight at sacrifice, median is presented, **p < 0.01 vs OVX
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such complication was observed in mice bearing these im-
plants. Kang et al. [32] showed that mortality rate was signif-
icantly reduced when mice received a lower but nonetheless
active dose of E2. Nevertheless, we do not exclude that this
side effect could vary with mouse strain and treatment dura-
tion. It should also be evaluated for the development of
patient-derived xenograft (PDX) model requiring very long-
term supplementation of E2.
The comparison of MP and RI presenting close in vitro
pharmacodynamics revealed overall similar impact on
B16K1 melanoma tumor growth. The differences observed
between both devices regarding the amplitude of the initial
burst of 2 days have no major impact on this readout.
However, standard errors and dispersion of tumor volume
and weight were significantly lower in RI treated group than
in MP one. This is in accordance with the standard deviations
and the coefficient of variation we measured in the in vitro and
in vivo release kinetics, as well as in plasma levels obtained at
the end of the experiment. Some disintegrated matrix pellets
were also found after sacrifice. This could contribute to the
larger variability in the MP group. The RI presents reduced
intra-group variability that could result from a better control of
release mechanisms as shown by in vitro pharmacodynamics.
Interestingly, our statistical power analysis revealed that the
use of RI could reduce the number of animal necessary to
reach sufficient statistical power in specific experiments.
This is of particular interest to achieve the Breduction^ criteria
of the 3Rs rule (Replacement, Reduction, Refinement) [35,
36]. These guidelines governing animal ethic are explicitly
required by EU legislation (http://eur-lex.europa.eu/legal-
content/EN/TXT/?qid=1468335661396&uri=CELEX:32010
L0063). Moreover, reduction of animal number to minimum
is a major concern for scientific working with experiment
animals not only for ethic, but also for scientific, legal and
economic purposes.
In conclusion, this work highlights that drug release mech-
anisms, MP or RI, used to deliver E2 could impact the amount
of E2 that is really deliver and the interindividual variability.
Depending on the dose-dependent sensitivity of the physio-
logical or pathological readout studied, careful attention
should be paid to choose the slow-releasing device that is
the most appropriated to a specific experiment. In the context
of ever increasing legal requirements for the welfare and pro-
tection of animals used for scientific purposes, the judicious
choice of a reliable and accurate drug release system will
fulfill the 3Rs rule.
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